FDA Accepts First Biosimilar Application under New Approval Pathway

by Akin Gump Strauss Hauer & Feld LLP
Contact

July 24, 2014 was a landmark day in the biotechnology industry: Sandoz (the generic arm of Novartis) announced that the U.S. Food and Drug Administration (FDA or “the Agency”) had accepted the first application for a U.S. biosimilar approval, for a biosimilar version of Amgen’s Neupogen (filgrastim). This marks the first application filed and accepted pursuant to the approval pathway established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Sandoz now enters unchartered territory, as FDA has yet to finalize its policies on biosimilars and the standards for their approval.

The BPCIA created a pathway to market for biological products that are “biosimilar” to, or “interchangeable” with, a reference FDA-licensed biologic. Biosimilars are manufactured with the goal of closely mirroring a licensed reference biological product—a complex medicine manufactured from living organisms. We do not know how quickly other biosimilar applications will be filed, but companies have clearly been laying the groundwork for submitting applications. During Fiscal Year 2013, FDA received 93 submissions for biosimilars in development and completed 81 actions related to these submissions.1 In connection with these biosimilars in development, FDA conducted three reviews of proprietary biosimilar product names and held 27 meetings—a mix of Initial Advisory Meetings and Type 2, Type 3 and Type 4 meetings within the Biosimilar Product Development (BPD) phase.2

FDA Implementation of Biosimilars Pathway

Sandoz’s application, which the company apparently filed in May, is further evidence that companies are pushing forward absent clear U.S. regulatory guidelines. FDA is still developing guidance implementing the new BPCIA pathway, which could take years to finalize. The Agency issued three Draft Guidances in February 2012, but only in May of this year released a Draft Guidance that delves more deeply into the studies needed to show biosimilarity. The Guidance topics, and release dates, include:

  • Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Draft Guidance): Intended to assist sponsors of a 351(k) biosimilar application in demonstrating that a proposed therapeutic protein product is biosimilar to a reference product. Issued February 2012; Formal comment period ended April 16, 2012.
  • Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (Draft Guidance): Provides analytical factors that FDA will consider in assessing whether a proposed therapeutic protein product is highly similar to a reference product. Issued February 2012; formal comment period ended April 16, 2012.
  • Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (Draft Guidance): Outlines FDA’s interpretation of the BPCIA, in the form of answers to common questions from potential biosimilar application sponsors, biologics application (BLA) holders and other stakeholders. Issued February 2012; formal comment period ended April 16, 2012.
  • Formal Meetings between the FDA and Biosimilar Biological Product Sponsors or Applicants (Draft Guidance): Provides recommendations to stakeholders on formal meetings between FDA and biosimilar sponsors or applicants during the biosimilar product development phase. Issued March 2013; formal comment period ended May 31, 2013.
  • Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (Draft Guidance): Provides a stepwise process—which includes clinical pharmacology studies—for demonstrating that a proposed biosimilar product is highly similar to a reference product, pursuant to a “totality of evidence” standard. Issued May 2014; formal comment period ends August 12, 2014.

In the absence of finalized FDA policy, many questions remain. In particular, FDA has yet to come down on whether biosimilars should have distinct nonproprietary names from the reference product. This topic has garnered significant interest nationally—both in Congress and within executive agencies including the Federal Trade Commission (FTC). The FTC hosted a workshop earlier this year that considered naming as part of a broader analysis of competition issues surrounding biologic and biosimilar products. The World Health Organization (WHO) is also considering the issue from an international perspective.

Another other key issue that may be addressed during the review of Sandoz’s application is “interchangeability,” whereby FDA concludes that the biologic can be expected to produce the same clinical result as the reference product in any given patient. Although Sandoz has declined to state whether it seeks an interchangeability designation, such a designation would allow Sandoz’s product to be widely substituted for the reference product. FDA has informally indicated its preference that sponsors first obtain biosimilar approval before requesting that FDA make a determination as to interchangeability, so it is possible that Sandoz will seek an interchangeability designation at a later time.

Patent Implications

A section 351(k) application can also be the triggering event for biosimilars patent litigation. Under the BPCIA, the 351(k) applicant has 20 days after filing to provide its application to the branded manufacturer. The branded manufacturer then has 60 days to provide a list of patents that it believes it could reasonably assert, kicking off a series of exchanges between the parties that determines which patents will be litigated in an immediate infringement suit prior to FDA approval of the biosimilar. Whether or not the Sandoz filgrastim application leads to patent litigation, the line-up of other biosimilars in development means that the first biosimilars patent lawsuit to test these provisions of the BPCIA is likely not far off.  

1 FY 2013 Performance Report to the President and Congress for the Biosimilar User Fee Act, available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/
UserFeeReports/PerformanceReports/UCM384179.pdf
.

2 A Biosimilar Initial Advisory Meeting is “limited to a general discussion regarding whether licensure under section 351(k) of the Public Health Service Act may be feasible for a particular product, and, if so, general advice on the expected content of the development program”; a BPD Type 1 Meeting is “necessary for an otherwise stalled drug development program to proceed . . ., a special protocol assessment meeting, or a meeting to address an important safety issue”; a BPD Type 2 Meeting is “a meeting to discuss a specific issue (e.g., proposed study design or endpoints) or questions where FDA will provide targeted advice regarding an ongoing biosimilar biological product development program”; a BPD Type 3 Meeting is an “in-depth data review and advice meeting regarding an ongoing biosimilar biological product development program”; and a BPD Type 4 Meeting is “a meeting to discuss the format and content of a biosimilar biological product application or supplement submitted under 351(k) of the PHS Act.” FY 2013 BsUFA Performance Report at B-1, B-2.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Akin Gump Strauss Hauer & Feld LLP | Attorney Advertising

Written by:

Akin Gump Strauss Hauer & Feld LLP
Contact
more
less

Akin Gump Strauss Hauer & Feld LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!